Abstract
Purpose: Candida auris (C. auris) was initially isolated in 2009 and has increased its prevalence globally. Many strains exhibit multidrug resistance to primary antifungal treatments, causing difficulty for healthcare professionals and poor outcomes for patients. The purpose of this study is to analyze clinical trials regarding treatment of C. auris infections due to increasing antimicrobial resistance.
Methods: An observational analysis was conducted of clinical trials from two databases. The National Library of Medicine’s Clinical Trials (Clinicaltrials.gov) was analyzed using ‘Candida auris’ and ‘Invasive candidiasis’ with ‘C. auris’ in the ‘other’ field. MEDLINE (PubMed.gov) was analyzed using ‘clinical trial,’ ‘phase,’ and ‘candida auris.’
Results: The search of CTG resulted in 7 unique trials with 1 additional trial found on PubMed. From these trials, 5 were interventional studies that used one of the following medications: fosmanogepix, oral ibrexafungerp (SCY-078), rezafungin, caspofungin, fluconazole, and intranasal 10% povidone-iodine. From these 5 trials, 2 have results with antifungal treatments NCT04148287 and NCT03667690.
Discussion/Conclusion: Publishing the results of clinical trials promptly is necessary to increase the amount of therapeutic research and continue the education of healthcare professionals and patients. It is necessary for the development of an effective and safe cure for C. auris infections.
Methods: An observational analysis was conducted of clinical trials from two databases. The National Library of Medicine’s Clinical Trials (Clinicaltrials.gov) was analyzed using ‘Candida auris’ and ‘Invasive candidiasis’ with ‘C. auris’ in the ‘other’ field. MEDLINE (PubMed.gov) was analyzed using ‘clinical trial,’ ‘phase,’ and ‘candida auris.’
Results: The search of CTG resulted in 7 unique trials with 1 additional trial found on PubMed. From these trials, 5 were interventional studies that used one of the following medications: fosmanogepix, oral ibrexafungerp (SCY-078), rezafungin, caspofungin, fluconazole, and intranasal 10% povidone-iodine. From these 5 trials, 2 have results with antifungal treatments NCT04148287 and NCT03667690.
Discussion/Conclusion: Publishing the results of clinical trials promptly is necessary to increase the amount of therapeutic research and continue the education of healthcare professionals and patients. It is necessary for the development of an effective and safe cure for C. auris infections.
Original language | American English |
---|---|
Pages | 65 |
State | Published - 13 Sep 2024 |
Event | 2024 Symposium on Tribal and Rural Innovations in Disparities and Equity for Health - Oklahoma State University College of Osteopathic Medicine at the Cherokee Nation, Tahlequah, United States Duration: 13 Sep 2024 → 13 Sep 2024 |
Conference
Conference | 2024 Symposium on Tribal and Rural Innovations in Disparities and Equity for Health |
---|---|
Abbreviated title | STRIDE 2024 |
Country/Territory | United States |
City | Tahlequah |
Period | 13/09/24 → 13/09/24 |